BAIAP2L2: A Potential Drug Target and Biomarker (G80115)

Target Name: BAIAP2L2

NCBI ID: G80115

BAIAP2L2

BAIAP2L2: A Potential Drug Target and Biomarker

Protein-related diseases are a leading cause of morbidity and mortality worldwide. The identification of potential drug targets and biomarkers is crucial for the development of new therapeutic approaches. In this article, we discuss BAIAP2L2, a protein that has been identified as a potential drug target and biomarker for various diseases.

Background

BAIAP2L2 (BAI1 associated protein 2 like 2) is a protein that is expressed in various tissues, including the brain, heart, and gastrointestinal tract. It is a member of the superfamily of B-type pleiotropic proteins (SPP), which are characterized by the presence of a nucleotide-binding oligomerization domain (NBD), a conserved coiled-coil region, and a C-terminal region that is involved in protein-protein interactions and signaling.

Disease-related studies have identified BAIAP2L2 as being involved in various diseases, including neurodegenerative disorders, cardiovascular diseases, and gastrointestinal diseases. Its involvement in these diseases has led to the speculation that BAIAP2L2 may be a drug target or biomarker.

Potential drug targets

BAIAP2L2 has been identified as a potential drug target due to its involvement in various diseases. In neurodegenerative disorders, BAIAP2L2 has been shown to be involved in the development and progression of neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and Huntington's disease.

Studies have also shown that BAIAP2L2 is involved in the development and progression of cardiovascular diseases, including myocardial infarction, hypertension, and stroke. In these conditions,BAIAP2L2 has been shown to play a role in the regulation of cellular signaling pathways that are involved in the development and progression of these diseases.

In addition to its involvement in neurodegenerative and cardiovascular diseases,BAIAP2L2 has also been shown to be involved in the development and progression of gastrointestinal diseases, including inflammatory bowel disease, irritable bowel syndrome, and diarrhea.

Potential biomarkers

BAIAP2L2 has also been identified as a potential biomarker for various diseases. Its involvement in the development and progression of neurodegenerative diseases has led to the speculation that BAIAP2L2 may be used as a biomarker for these conditions. Similarly, its involvement in the development and progression of cardiovascular diseases has led to the suggestion that BAIAP2L2 may be used as a biomarker for these conditions.

In addition to its potential as a drug target,BAIAP2L2 has also been shown to be a potential biomarker for gastrointestinal diseases. Its involvement in the regulation of cellular signaling pathways that are involved in the development and progression of inflammatory bowel disease, irritable bowel syndrome, and diarrhea has led to these conditions being considered as potential biomarkers for BAIAP2L2.

Conclusion

In conclusion,BAIAP2L2 is a protein that has been identified as a potential drug target and biomarker for various diseases. Its involvement in the development and progression of neurodegenerative, cardiovascular, and gastrointestinal diseases makes it an attractive target for therapeutic intervention. Further research is needed to determine the full extent of its potential as a drug target and biomarker.

Protein Name: BAR/IMD Domain Containing Adaptor Protein 2 Like 2

Functions: Phosphoinositides-binding protein that induces the formation of planar or gently curved membrane structures. Binds to phosphoinositides, including to phosphatidylinositol 4,5-bisphosphate (PtdIns(4,5)P2) headgroups. There seems to be no clear preference for a specific phosphoinositide (By similarity)

The "BAIAP2L2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about BAIAP2L2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets